ARTICLE
|
doi:10.20944/preprints202212.0542.v2
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
safety analysis; targeted therapy; monoclonal antibody therapy; immune checkpoint inhibibitors; tyrosine kinase inhibitors; breast cancer; gynecological cancer; Helixor; Viscum album L.; PARP inhibitors; CDK 4/6 inhibitors
Online: 30 December 2022 (12:00:35 CET)